New research by Robin Patel, M.D. and others at Mayo Clinic has found that the use of a “transcriptomic-based cellular deconvolution tool” called CIBERSORTx could help improve the detection of infectious...
Neurofascin 155 IgG4 Antibody Test [Test in Focus] - Insights
John Mills, Ph.D., explains Mayo Clinic Laboratories' new neurofascin 155 (NF155) IgG4 antibody test, which is the first commercially available test in the U.S. to use flow cytometry to detect for NF155...
Converging on a major milestone in digital pathology - Insights
Successful implementation of a new slide scanning and analysis platform across five laboratories represents a significant step forward in Mayo Clinic’s digital pathology program — an initiative that combines...
Mayo Clinic Laboratory and Pathology Research Roundup: December 12 - Insights
This week's research roundup feature: Most patients with solitary bone plasmacytomas (SBP) progress to multiple myeloma (MM) after definitive radiation therapy as their primary treatment. Whether the presence of high-risk (HR) cytogenetic...
Mayo Clinic Laboratory and pathology research roundup: February 21 - Insights
This week's Research Roundup features: Predicting amyloid PET and tau PET stages with plasma biomarkers.
How an ex-NFL Linebacker Overcame His Greatest Opponent, Amyloidosis - Insights
six-year medical journey in search for answers. Finally, he was diagnosed with amyloidosis using a new testing methodology at Mayo Clinic....
Membranous nephropathy assay: PMND1 - Insights
John Lieske, M.D., describes Mayo Clinic Laboratories' new test for primary membranous nephropathy. PMND1 is a diagnostic cascade that provides a cost-effective approach to detecting antigens known to...
Kelch-11 Autoantibody Test [Test in Focus] - Insights
Divyanshu (Div) Dubey, M.B.B.S., explains how Mayo Clinic Labs’ new Kelch-11 antibody test — the first in the world — can confirm diagnosis, guide treatment, and improve outcomes in patients affected by...
Direct Ethanol Biomarker Testing: PETH - Insights
Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' new direct biomarker test for alcohol consumption. PETH is a blood test with a window of detection of about two to four weeks — compared with five...
Assay monitors response to monoclonal antibody therapy: Maria Alice Willrich, Ph.D. - Insights
Maria Alice Willrich, Ph.D., explains how Mayo Clinic Laboratories' new assay provides therapeutic drug monitoring of risankizumab, or RISA. Test results help guide care for patients with plaque psoriasis...